Communiqués Mesoblast Limited

Actions

MSB

AU000000MSB8

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:11:29 18/09/2026			Varia. 5j.	Varia. 1 janv.
2,110 ^AUD	+2,43%		-1,86%	-22,43%

27/08	Mesoblast : réduction de la perte et hausse du chiffre d'affaires pour l'exercice 2026	MT
27/08	Transcript : Mesoblast Limited, 2026 Earnings Call, Aug 26, 2026

Communiqués

27/08	Mesoblast : Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)	PU
27/08	Mesoblast Reports Substantial Revenue Growth to US$120M	AQ
24/08	Mesoblast Financial Results and Corporate Update Webcast	AQ
17/08	Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain	AQ
30/07	Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch	AQ
14/07	Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain	AQ
10/07	Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026	AQ
01/07	Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs	AQ
25/06	Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility	AQ
30/04	Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million	AQ
29/04	Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain	AQ
15/04	Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products	AQ
13/04	Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil(R) in Duchenne Muscular Dystrophy - CORRECTION	AQ
08/04	Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation	AQ
08/04	Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy	AQ
07/04	Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter	AQ
18/03	Mesoblast to Host R&D Day on April 8, 2026	AQ
12/03	Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast	AQ
27/02	Ryoncil® Profits Underpinning Substantial Growth Pipeline	AQ
23/02	MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST	AQ
20/02	Mesoblast Financial Results and Corporate Update Webcast	AQ
12/02	MESOBLAST LTD - HIGH SURVIVAL RATES WITH RYONCIL IN EIND PROGRAM EMPHASIZE IMPORTANCE OF EARLIER USE IN BOTH CHILDREN AND ADULTS WITH SR-aGvHD	AQ
12/02	High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD	AQ
29/01	Ryoncil® Net Revenues Increase for the Quarter to US$30M	AQ
27/01	Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment	AQ